Q4FY19 revenue grew by 22% YoY driven by higher sales in Formulations (FD) (~47%YoY) segments and API (Active Pharmaceutical Ingredient)(~19%YoY). EBITDA registered a 83% growth YoY while margin declined by 200bps to 16% on account of higher other expenses. PAT is up by 123% YoY due to higher profit from the joint venture business (Rs19cr vs Rs3cr %YoY)....